enoxaparin


Also found in: Medical, Wikipedia.

e·nox·a·par·in

 (ē′nŏk′sə-pâr′ĭn)
n.
A drug, C26H42N2O37S5, used in its sodium form in the prevention and treatment of deep vein thrombosis and in the treatment of heart attack and unstable angina.

[enoxa-, origin unknown + -parin, depolymerized heparin suffix (from (he)parin).]
References in periodicals archive ?
The Global Low Molecular Weight Heparin Market, by Drug (Enoxaparin, Dalteparin, Nadroparin, Bemiparin, Tinzaparin, and Others), by Packaging (Multi-vials and Prefilled Syringes), by Application (Deep Vein Thrombosis, Acute Coronary Syndrome (ACS), Pulmonary Embolism and Atrial Fibrillation), by End Use (Hospitals (Private and Public), Clinics, and Home) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued US$ 3,050.4 million in 2018, and is projected to exhibit a CAGR of 6.7% during the forecast period (2018 - 2026) as highlighted in a new report published by Coherent Market Insights.
Supply of enoxaparin sodium in a range of presentations.
Momenta Pharmaceuticals (MNTA) announced that Momenta, Sandoz AG and Amphastar Pharmaceuticals (AMPH) have executed a mutually agreeable settlement agreement resolving all pending litigation between the parties related to enoxaparin sodium injection.
Study patients received one of two types of blood thinners before surgery: subcutaneous enoxaparin, which lowers the activity of clotting proteins in the blood, and unfractionated heparin (UFH), which works with a natural protein in the body to block clot formation.
All patients received postoperative epidural analgesia and concomitant thromboprophylaxis with enoxaparin. Epidural was placed/removed 24 hours after the last dose of enoxaparin.
Objective: To determine the effectiveness and safety of enoxaparin as anticoagulant in patients undergoing elective percutaneous coronary intervention for stable coronary artery disease.
Low-molecular weight heparin (LMWH) (e.g., enoxaparin [Lovenox[R]]) is used widely to reduce patients' risk of harmful clot formation.
These data are claimed to support the use of LIXIANA as an effective and safe alternative to the best possible conventional treatment with enoxaparin and warfarin.
[13] We explored the effects of LMWH (subcutaneous enoxaparin) in our settings.
In this study we produced and characterized nanoparticles of PCL and chitosan as carriers of LMWH, enoxaparin. We also investigated the antithrombotic effect through oral and subcutaneous administration in animal models of venous thrombosis.
In the present study, enoxaparin, a low molecular weight heparin, was used as an anticoagulant to prevent thrombosis.